Appendix cancer differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(37 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__


'''For the WikiDoc page for this topic, click [[Appendix cancer|here]]'''
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Appendix_cancer]]


{{CMG}}; {{AE}} {{Soroush}}
{{CMG}}; {{AE}} {{Soroush}}


==Overview==
==Overview==
Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.
[[Vermiform appendix|Appendix]] [[cancer]] must be [[Appendix cancer differential diagnosis|differentiated]] from [[Benign|benign appendix lesions]] ([[mucocele]], [[Appendicitis|acute appendicitis]]), [[Colorectal cancer|colorectal cancers]], [[Ovarian cancer|adenexal masses]] ([[Ovarian cancer|ovarian tumors]]), and [[Neuroendocrine tumors|carcinoid tumors of the other organs]].


==Differentiating appendix cancer from other Diseases==
==Differentiating appendix cancer from other Diseases==
*Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.  
*[[Vermiform appendix|Appendix]] [[cancer]] must be [[Appendix cancer differential diagnosis|differentiated]] from [[Benign|benign appendix lesions]] ([[mucocele]], [[Appendicitis|acute appendicitis]]), [[Colorectal cancer|colorectal cancers]], [[Ovarian cancer|adenexal masses]] ([[Ovarian cancer|ovarian tumors]]), and [[Neuroendocrine tumors|carcinoid tumors of the other organs]].  
*As appendix cancer manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype.  
*As [[appendix cancer]] manifests in a variety of [[clinical]] forms, differentiation must be established in accordance with the particular subtype.  
:*Carcinoid tumors must be differentiated from other diseases that causecarcinoid syndrome, such as palpitation, facial flushing, diarrhea, .  
:*[[Carcinoid Tumor|Carcinoid tumors]] must be differentiated from other diseases that cause [[carcinoid syndrome]] sign and symptoms such as [[palpitation]], [[Flushing|facial flushing]], and [[diarrhea]].  
:*In contrast, adenocarcinomas and cystadenocarcinomas must be differentiated from other diseases that cause acute appendicitis or present with pseudomyxoma peritonei, such as colorectal cancers, appendix mucoceles.
:*In contrast, [[adenocarcinoma]]<nowiki/>s and cystadenocarcinomas must be differentiated from other diseases that cause [[Appendicitis|acute appendicitis]] or present with [[pseudomyxoma peritonei]], such as [[Colorectal cancer|colorectal cancers]] and [[Appendix cancer echocardiography and ultrasound|appendix mucoceles]].
 
<small>
{| class="wikitable"
{| class="wikitable"
|-  
|-  
Line 25: Line 25:
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histo-
pathology
|-  
|-  
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdo-<br>minal<br>pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdo-<br>minal<br>pain'''
Line 63: Line 64:
|-
|-
| rowspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix cancer
| rowspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix cancer
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Adenocarcinoma<small><sup>1</sup></small>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Adenocarcinoma|Adeno-]]
[[Adenocarcinoma|carcinoma]]<small><sup>1</sup></small>
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px;" | -/+
| style="background: #F5F5F5; padding: 5px;" | -/+
| style="background: #F5F5F5; padding: 5px;" | <math>\downarrow</math>
| style="background: #F5F5F5; padding: 5px;" | <math>\downarrow</math>
| rowspan="1" style="background: #F5F5F5; padding: 5px;" |
| rowspan="1" style="background: #F5F5F5; padding: 5px;" |
* '''Generally asympto-<br>matic'''  
* '''Generally [[Asymptomatic|asympto-<br>matic]]'''  
* Appendicitis symptoms  
* [[Appendicitis]] [[Symptom|symptoms]]
* [[Nausea and vomiting|Nausea<br>&<br>vomiting]],<br>[decreased<br>appetite]]<br>(anorexia)
* [[Nausea and vomiting|Nausea<br>&<br>vomiting]],<br>decreased<br>[[appetite]]
* No gas<br>or<br>stool pass<br>(intestinal<br>obstruction)  
* No gas<br>or<br>stool pass<br>([[Bowel obstruction|intestinal<br>obstruction]])  
* Bone pain<br>(bone<br>metastasis)  
* [[Bone pain]]<br>(bone<br>[[Metastasis|metastasis)]]
* Bloating<br>(ascites)  
* [[Bloating]]<br>([[ascites]])  
| style="background: #F5F5F5; padding: 5px;" | -  
| style="background: #F5F5F5; padding: 5px;" | -  
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Ascites]]  
* [[Ascites]]  
* Shifting            dullness  
* [[Shifting            dullness]]


| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* CEA  
* [[CEA]]
* CA 19-9  
* [[CA 19-9]]
*   
*   
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
* Soft<br>tissue<br>thickening
* Soft<br>tissue<br>thickening
* Wall<br> irregularity
* Wall<br> irregularity
* Presence<br>of<br> pseudo-<br>myxoma<br>peritonei
* Presence<br>of<br> [[Pseudomyxoma peritonei|pseudo-<br>myxoma<br>peritonei]]
* Calcification
* [[Calcification]]
* Internal<br>septations
* Internal<br>septations
* Peri<br>appendiceal<br>fat<br>stranding<br>nd<br>intra-<br>peritoneal<br>free fluid<br> which is a<br> nonspecific<br> finding
* Peri<br>appendiceal<br>fat<br>stranding<br>and<br>intra-<br>peritoneal<br>free fluid<br> which is a<br> nonspecific<br> finding
* Cystic<br> lesion
* Cystic<br> lesion
*  
*  
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
* Diffusion<br>weighted<br>MRI<br>has<br>been<br>shown to<br>be<br>the<br>modality<br>of choice<br>for<br>''peritoneal<br>carcino-<br>matosis''
* Diffusion<br>weighted<br>[[Magnetic resonance imaging|MRI]]<br>has<br>been<br>shown to<br>be<br>the<br>modality<br>of choice<br>for<br>''[[Peritoneal carcinomatosis|peritoneal<br>carcino-<br>matosis]]''
* Increased<br>fluid<br>signal on<br>T2 weighted sequence
* Increased<br>fluid<br>signal on<br>T2 weighted sequence
* Soft<br> tissue<br> mass in<br> the<br>[[appendix]]
* Soft<br> tissue<br> mass in<br> the<br>[[appendix]]
Line 104: Line 106:
* Distinct<br> appendix<br> wall<br> layers
* Distinct<br> appendix<br> wall<br> layers
| style="background: #F5F5F5; padding: 5px;" |[[Positron emission tomography|Positron<br>emission<br>tomography]]<br>(PET)
| style="background: #F5F5F5; padding: 5px;" |[[Positron emission tomography|Positron<br>emission<br>tomography]]<br>(PET)
| style="background: #F5F5F5; padding: 5px;" |'''Gross pathology''':
| style="background: #F5F5F5; padding: 5px;" |'''Gross<br>[[pathology]]''':
* Gray/yellow color
* Gray/yellow<br>color


* Cystic structures with angiolymphatic invasion
* Cystic<br>structures<br>with<br>angiolymphatic<br>invasion
* Appendix might be buried within the mass
* [[Vermiform appendix|Appendix]]<br>might be<br>buried<br>within<br>the mass
'''Microscopic pathology:'''
'''Microscopic<br>pathology:'''
* Intestinal, mucinous or signet ring cell types
* Intestinal,<br>mucinous<br>or<br>[[Signet ring cell carcinoma|signet ring<br>cell]] types
* Coexisting acute appendicitis is common
* Coexisting<br>[[Appendicitis|acute<br>appendicitis]]<br>is common
'''IHC''' might be positive for the following '''stains:'''
'''[[Immunohistochemistry|IHC]]:'''
* MUC 2  
* MUC 2  
* '''MUC5AC'''  
* '''MUC5AC'''  
Line 120: Line 122:
* CK 20
* CK 20
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Carcinoid Tumor|Carcinoid]]
[[Carcinoid Tumor|tumor]]<sup>2</sup>
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | <math>\uparrow</math>
| style="background: #F5F5F5; padding: 5px;" | <math>\uparrow</math>
| rowspan="1" style="background: #F5F5F5; padding: 5px;" |
| rowspan="1" style="background: #F5F5F5; padding: 5px;" |
* '''Generally asympto-<br>matic'''
* '''Generally [[Asymptomatic|asympto-<br>matic]]'''
* Flushing  
* [[Flushing]]
* Palpitation  
* [[Palpitation]]
* Dyspnea  
* [[Dyspnea]]
*   
*   
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* TR<br>murmur
* [[Tricuspid regurgitation|TR]]<br>[[Heart murmur|murmur]]
* Wheezing
* [[Wheeze|Wheezing]]
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Ki67:<br> a reliable <br>marker of <br>cell <br>proliferation  
Ki67:<br>a reliable<br>marker of<br>cell<br>proliferation  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Somatostatin]]<br>[[scintigraphy]]<br>with<br> 111-indium-<br>octreotide
* [[Somatostatin]]<br>[[scintigraphy]]<br>with<br> 111-indium-<br>octreotide
* [[Bone]]<br>[[scintigraphy]]<br> with<br> 99mTc-<br>methylene<br> diphosphonate<br>(99mTcMDP)
* [[Bone]]<br>[[scintigraphy]]<br> with<br> 99mTc-<br>methylene<br> diphosphonate<br>(99mTcMDP)
* Positron<br>emission<br>tomography<br>(PET)
* Positron<br>emission<br>tomography<br>(PET)
| style="background: #F5F5F5; padding: 5px;" |'''Gross pathology''':
| style="background: #F5F5F5; padding: 5px;" |'''Gross<br>[[pathology]]''':
** Prevalent<br>at the<br>tip of<br>appendix
* [[Prevalence|Prevalent]]<br>at the<br>tip of<br>[[Vermiform appendix|appendix]]
** Generally<br>less than<br>1 cm
* Generally<br>less than<br>1 cm
** Gray or yellow
* Gray or <br>yellow
** Well-demarcated firm
* Well-<br>demarcated<br>firm
** Intramural<br>nodules<br>that may<br>narrow or<br>obliterate<br>appendiceal<br> lumen
* Intramural<br>nodules<br>that may<br>narrow or<br>obliterate<br>appendiceal<br> lumen
** Proximal<br>tumors<br>may cause<br>obstruction<br>and<br>appendicitis
* Proximal<br>tumors<br>may cause<br>obstruction<br>and<br>appendicitis
'''Microscopic pathology:'''
'''Microscopic<br>pathology:'''


*Insular growth pattern of solid islands of uniform polygonal cells with minimal pleomorphism
*Insular<br>growth<br>pattern<br>of solid<br>islands of<br>uniform<br>polygonal<br>cells with<br>minimal<br>pleomorphism


*Retraction of peripheral tumor cells from stroma
*Retraction<br>of<br>peripheral<br>tumor<br>cells from<br> stroma


*Angiolymphatic invasion is common
*Angio-<br>lymphatic<br>invasion<br>is common


*Granular eosinophilic cytoplasm with either diffusely scattered or peripherally clumped granules
*Granular<br>eosinophilic<br>cytoplasm<br>with either<br>diffusely<br>scattered<br>or<br>peripherally<br>clumped<br>granules


*Two types of well differentiated tumors: EC cell (serotonin producing) and rarely L-cell (enteroglucagon or peptide YY producing)
*Two types<br>of well<br>differentiated<br>tumors:<br> EC cell <br>(serotonin<br> producing) <br>and rarely<br> L-cell<br> (enteroglucagon<br>or <br>peptide YY <br>producing)


'''IHC''' might be positive for '''S100'''
[[Immunohistochemistry|'''IHC''']]''':'''
*Might be<br> positive for <br>'''S100'''
|-
|-
| style="background: #DCDCDC; padding: 5px;" |Goblet cell carcinoid
| style="background: #DCDCDC; padding: 5px;" |Goblet
cell  
 
carcinoid
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px;" | +/-
Line 183: Line 190:
* '''CK 20'''   
* '''CK 20'''   
* '''CK 7'''  
* '''CK 7'''  
* Synapthosin  
* [[Synapthosin|Synap-          thosin]]
* pancreatic polypeptide  
* pancreatic polypeptide  
* CEA  
* [[CEA]]
* CA 19-9  
* [[CA 19-9]]
* CA 125  
* [[CA-125|CA -125]]
| colspan="4" style="background: #F5F5F5; padding: 5px;" |Unfortunately,<br> compared to the other carcinoid tumors of appendix,<br> GCC is more aggressive and <br>patients with GCC generally present at higher stages.<br> Hence, in addition to<br> the above mentioned <br>general findings for appendix cancers, <br>imaging studies should <br>look for evidences of peritoneal involvement,<br> bone metastasis, lymphadenopathy, <br>and metastatic lesions<br> in ovaries and/or prostate.  
| colspan="4" style="background: #F5F5F5; padding: 5px;" |Unfortunately,<br> compared to the other carcinoid tumors of appendix,<br> GCC is more aggressive and <br>patients with GCC generally present at higher stages.<br> Hence, in addition to<br> the above mentioned <br>general findings for appendix cancers, <br>imaging studies should <br>look for evidences of peritoneal involvement,<br> bone metastasis, lymphadenopathy, <br>and metastatic lesions<br> in ovaries and/or prostate.  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
'''Gross pathology''':
'''Gross<br>pathology''':
:* No gross tumor might be present  
* No gross<br>tumor might<br>be present  
:* Thickened appendiceal wall  
* Thickened<br>appendiceal<br>wall  
'''Microscopic appearance:'''  
'''Microscopic<br>appearance:'''  
*GCC Generally spares mucosa and infiltrates muscularis propria and periappendiceal fat
*GCC Generally<br>spares mucosa<br>and<br>infiltrates<br>muscularis<br>propria<br>and<br>peri-<br>appendiceal<br> fat
*Tumor cell clusters  
*Tumor<br> cell clusters  
*Crypt-like structures  
*Crypt-like<br> structures  
*Tubules of mucus-secreting cells distended with mucin resembling goblet cells
*Tubules of<br> mucus-secreting <br>cells distended<br> with mucin <br>resembling<br> goblet cells
*Eosinophilic cytoplasm resembling carcinoid tumors
*Eosinophilic<br> cytoplasm <br>resembling<br> carcinoid <br>tumors
*Pools of extracellular mucin
*Pools of <br>extracellular<br> mucin
*Scattered Paneth cells in tumors with crypt like structures
*Scattered<br>Paneth cells<br>in tumors<br>with crypt<br>like<br>structures
*Extensive perineural invasion  
*Extensive<br>perineural<br>invasion  
*'''Carcinomatous growth pattern:'''
*'''Carcinomatous<br>growth<br>pattern:'''  
::*Cribriform growth pattern, solid sheets of infiltrating signet ring cells
*Cribriform<br>growth<br>pattern,<br>solid<br>sheets of<br>infiltrating<br>signet ring<br>cells
::*Nuclear pleomorphism  
*Nuclear<br>pleomorphism  
::*Increased mitotic activity
*Increased<br>mitotic<br>activity
|-  
|-  
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
Line 242: Line 249:


modalities
modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histo-
pathology
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix Mucocele
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix Mucocele
| style="background: #DCDCDC; padding: 5px;" |Mucosal hyperlasia
| style="background: #DCDCDC; padding: 5px;" |Mucosal
[[hyperplasia]]
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
Line 260: Line 269:
*  
*  
* low<br>attenuation<br> well<br> defined<br> mass in<br> RLQ<br>near<br>cecum
* low<br>attenuation<br> well<br> defined<br> mass in<br> RLQ<br>near<br>cecum
* Inflammation<br> is the key to<br> distinguish<br> between<br> appendicitis<br> and<br> mucocele
* [[Inflammation]]<br> is the key to<br> distinguish<br> between<br> appendicitis<br> and<br> mucocele
* Wall<br> thickness<br>'''does not'''<br> distinguish<br> between<br> malignant <br>and <br>benign<br> mucocele
* Wall<br> thickness<br>'''does not'''<br> distinguish<br> between<br> malignant <br>and <br>benign<br> mucocele
* Intramural<br> nodule <br>is a sign of<br> neoplastic<br> lesions. <sup>4</sup>  
* Intramural<br> nodule <br>is a sign of<br> neoplastic<br> lesions. <sup>4</sup>  
Line 272: Line 281:
* Thin<br>appendiceal<br>wall  
* Thin<br>appendiceal<br>wall  
* A focus<br>of<br>hyper-<br>echogenicity
* A focus<br>of<br>hyper-<br>echogenicity
* '''Since<br> generally<br> there is<br> no inflammation'''
* '''Since<br> generally<br> there is<br> no [[inflammation]]'''
* Surrounding <br>fat<br> is normal.  
* Surrounding <br>fat<br> is normal.  
* No peri-<br>appendiceal <br>fluid or<br>collection
* No peri-<br>appendiceal <br>fluid or<br>collection
| rowspan="4" style="background: #F5F5F5; padding: 5px;" |N/A
| rowspan="4" style="background: #F5F5F5; padding: 5px;" |N/A
| style="background: #F5F5F5; padding: 5px;" |Similar to hyperplastic colon polyp
| style="background: #F5F5F5; padding: 5px;" |Similar<br>to<br>hyperplastic<br>colon<br>polyp
|-
|-
| style="background: #DCDCDC; padding: 5px;" |Simple or retention cyst
| style="background: #DCDCDC; padding: 5px;" |Simple
or
 
[[Mucous retention cyst|retention]]
 
[[Mucous retention cyst|cyst]]
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
Line 287: Line 301:
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |N/A
| style="background: #F5F5F5; padding: 5px;" |N/A
| style="background: #F5F5F5; padding: 5px;" |Degenerative epithelial changes because of obstruction
| style="background: #F5F5F5; padding: 5px;" |Degenerative<br>epithelial<br>changes<br>because of<br>obstruction
|-
|-
| style="background: #DCDCDC; padding: 5px;" | Mucinous cystadenomas
| style="background: #DCDCDC; padding: 5px;" | Mucinous cyst-
adenomas
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
Line 299: Line 314:
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |If develop  
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |If develop  
pseudo-<br>myxoma<br> peritonei:<br>
[[Pseudomyxoma peritonei|pseudo-<br>myxoma<br> peritonei]]:<br>
* [[Ascites]]  
* [[Ascites]]  
* Shifting<br>dullness  
* [[Shifting dullness|Shifting<br>dullness]]
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* CEA  
* [[CEA]]
* CA 19-9  
* [[CA 19-9]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Histologically<br>benign
* Histo-<br>logically<br>benign
* Similar to colon adenomatous polyps or villous adnomas
* Similar<br>to<br>colon<br>adenomatous<br>polyps or<br> villous <br>adnomas
|-
|-
| style="background: #DCDCDC; padding: 5px;" |  Mucinous cystadenocarcinomas
| style="background: #DCDCDC; padding: 5px;" |  Mucinous [[Cystadenocarcinoma staging|cystadeno-]]
[[Cystadenocarcinoma staging|carcinomas]]
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
Line 319: Line 335:
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* CEA  
* [[CEA]]
* CA 19-9  
* [[CA 19-9]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Glandular invasion into the stoma
* Glandular<br>invasion<br>into the<br>stoma
* Pseudomyxoma peritonei
* Pseudo-<br>myxoma<br>peritonei
|-  
|-  
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdo-<br>minal<br>pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Abdo-<br>minal<br>pain'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Change in girdle size
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bowel
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bowel<br>freq-<br>uency
freq-
 
uency
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |  '''Other'''  
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |  '''Other'''  
'''symptoms'''
'''symptoms'''
Line 337: Line 350:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdo-<br>minal<br> tender-<br>ness
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Abdo-<br>minal<br> tender-<br>ness
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
physical  
physical<br>exami-<br>nation<br>findings
 
exami-
 
nation  
 
findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''5-HIAA<br>and/or<br>CgA'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''5-HIAA<br>and/or<br>CgA'''
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other lab findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other lab findings
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CT scan
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CT scan
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MRI
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MRI
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Utra-
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Utra-<br>sounography<br>
sounography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other<br>diagnostic<br>studies<br>and<br>imaging<br>modalities<br>
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histo-
diagnostic
pathology
 
studies
 
and
 
imaging
 
modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Ovarian cancer differential diagnosis|Ovarian cancer]]
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | [[Ovarian cancer differential diagnosis|Ovarian cancer]]
Line 367: Line 365:
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki><math>\downarrow</math>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki><math>\downarrow</math>
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Pelvic/          abdominal        pain or          pressure  
* Pelvic/          [[abdominal        pain]] or          pressure  
* Vaginal          bleeding/  discharge  
* [[Vaginal          bleeding]]/  discharge  
* Dyspnea  
* [[Dyspnea|Dyspne]]<nowiki/>a
* GI                disturbance  
* GI                disturbance  
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
Line 375: Line 373:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Ascites]]  
* [[Ascites]]  
* Shifting          dullness  
* [[Shifting          dullness]]
* Fever  
* [[Fever]]
* Pleural      effusion  
* [[Pleural      effusion]]
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* '''Depends<br>on<br>the<br>underlying<br>etiology'''
* '''Depends<br>on<br>the<br>underlying<br>etiology'''
* Iron
* Iron
* HCG
* [[Human chorionic gonadotropin|HCG]]
* LDH
* [[Lactate dehydrogenase|LDH]]
* Calcium
* [[Calcium]]
* Estrogen
* [[Estrogen]]
* Progestron
* Progestron
* Testos-         terone  
* [[Testosterone|Testos-<br>terone]]
* AFP
* [[Alpha-fetoprotein|AFP]]
* CA 125
* [[CA-125]]
* Ki 67
* Ki 67
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 399: Line 397:
* Pleural <br>effusion
* Pleural <br>effusion
* Peritoneal<br>involvement
* Peritoneal<br>involvement
* Lympha-denopathy
* [[Lymphadenopathy|Lympha-denopathy]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Adnexal <br> mass
* Adnexal <br> mass
Line 418: Line 416:
* Calcification
* Calcification
| style="background: #F5F5F5; padding: 5px;" | N/A
| style="background: #F5F5F5; padding: 5px;" | N/A
| style="background: #F5F5F5; padding: 5px;" | Depends on the tumor type. You may find the details [[Ovarian cancer differential diagnosis|here]].
| style="background: #F5F5F5; padding: 5px;" | Depends<br>on the<br>tumor type.<br>You may<br>find the<br>details<br>[[Ovarian cancer differential diagnosis|here]].
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Colorectal cancer]]
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Colorectal cancer]]
Line 442: Line 440:
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |'''Colonoscopy'''
| style="background: #F5F5F5; padding: 5px;" |'''Colonoscopy'''
''Adeno-''
''[[Adenocarcinoma|Adeno-]]''


''carcinoma''
''[[Adenocarcinoma|carcinoma]]''
* [[Polyp|Polyps]]<br>(villous,<br>tubular,<br>tubulo-<br>villous)
* [[Polyp|Polyps]]<br>(villous,<br>tubular,<br>tubulo-<br>villous)
* [[Ulcer|Ulcerating<br>polyps]]
* [[Ulcer|Ulcerating<br>polyps]]
Line 451: Line 449:
* [[Infiltration (medical)|Infiltrating]], [[Ulceration|ulcerating]]<br>or<br>fungating<br>lesions in<br>the<br> wall of<br>colon
* [[Infiltration (medical)|Infiltrating]], [[Ulceration|ulcerating]]<br>or<br>fungating<br>lesions in<br>the<br> wall of<br>colon


| style="background: #F5F5F5; padding: 5px;" |<nowiki>-/+(Carcinoid tumors)</nowiki>
| style="background: #F5F5F5; padding: 5px;" | -/+([[Carcinoid Tumor|Carcinoid tumor]]<nowiki/>s)
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Anemia]]
* [[Anemia]]
* Positive         [[Fecal occult blood test]]
* Positive<br>fecal<br>occult<br>blood<br>test
* High<br>levels<br>of<br>[[CEA]]                 and                   [[CA 19-9]]
* High<br>levels<br>of<br>[[CEA]]<br>and<br>[[CA 19-9]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
*luminal<br>narrowing<br>
*luminal<br>narrowing<br>
Line 463: Line 461:
*[[Metastases|Hepatic<br>metastases]],
*[[Metastases|Hepatic<br>metastases]],
*Intestinal<br>perforation,<br>
*Intestinal<br>perforation,<br>
*Enlarged<br>lymph<br>nodes
*[[Lymphadenopathy|Enlarged<br>lymph<br>nodes]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Tumor]]<br> mass<br> and <br>the<br> extension<br> of<br> [[tumor]] to<br> other<br> structures
* [[Tumor]]<br> mass<br> and <br>the<br> extension<br> of<br> [[tumor]] to<br> other<br> structures
Line 469: Line 467:
* [[liver]],<br>[[lung]]<br>and<br>[[brain]]<br>[[Metastasis]]  
* [[liver]],<br>[[lung]]<br>and<br>[[brain]]<br>[[Metastasis]]  
| style="background: #F5F5F5; padding: 5px;" |Generally<br>not<br>recommended:<br>may<br>evaluate<br>liver metastasis<br>or presence<br>of fluid<br>in abdominal<br>cavity, but it is <br>neither <br>sensitive<br> nor<br> specific.
| style="background: #F5F5F5; padding: 5px;" |Generally<br>not<br>recommended:<br>may<br>evaluate<br>liver metastasis<br>or presence<br>of fluid<br>in abdominal<br>cavity, but it is <br>neither <br>sensitive<br> nor<br> specific.
| style="background: #F5F5F5; padding: 5px;" |PET<br>scan,<br>Endoscopy,<br>Colonoscopy,  
| style="background: #F5F5F5; padding: 5px;" |[[Positron emission tomography|PET<br>scan]],<br>[[Endoscopy]],<br>[[Colonoscopy]],  


Barium enema
[[Lower gastrointestinal series|Barium enema]]


| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Depends on the tumor type.. You will find more information [[Colorectal cancer differential diagnosis|here]]
* Depends<br>on the<br>tumor<br>type.<br>You will<br>find more<br>information<br>[[Colorectal cancer differential diagnosis|here]]
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Pseudomyxoma peritonei differential diagnosis|Pseudomyxoma peritonei]]
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Pseudomyxoma peritonei differential diagnosis|Pseudomyxoma]]
[[Pseudomyxoma peritonei differential diagnosis|peritonei]]
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
Line 485: Line 484:
| style="background: #F5F5F5; padding: 5px;" |[[Ascites]]
| style="background: #F5F5F5; padding: 5px;" |[[Ascites]]


Shifting              dullness
[[Shifting              dullness]]
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Non specific
* Nonspecific
* Depends             on the         etiology               of the         disease
* Depends<br>on the<br>[[etiology]]<br>of the<br>disease
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Low-<br>attenuation<br>Scalloping<br> of the<br> visceral<br> surfaces<br> differentiates<br> pseudo-<br>myxoma <br>from other<br> causes of<br> peritnoitis.
* Low-<br>attenuation<br>Scalloping<br> of the<br> visceral<br> surfaces<br> differentiates<br> [[Pseudomyxoma peritonei|pseudo-<br>myxoma]] <br>from other<br> causes of<br>[[peritonitis]].
* Typically <br>does not <br>invade<br> visceral <br>organs<br> or spread<br> by [[lymphatic]]<br> or<br> hemato-<br>genous <br>routes <br>unlike<br>mucinous<br>carcino-<br>matosis
* Typically <br>does not <br>invade<br> visceral <br>organs<br> or spread<br> by [[lymphatic]]<br> or<br> hemato-<br>genous <br>routes <br>unlike<br>mucinous<br>carcino-<br>matosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Charact-<br> erized <br>by a mass<br>which is<br>hypointense<br>on<br>T1-weighted<br>MRI<br>and<br>hyperintense<br>on<br>T2-weighted<br>MRI.<br>MRI has<br> better<br>sensitivity<br>in<br>detecting<br>ascites<br>fluid <br>           and<br>mucocele.
Charact-<br> erized <br>by a mass<br>which is<br>hypointense<br>on<br>T1-weighted<br>MRI<br>and<br>hyperintense<br>on<br>T2-weighted<br>[[Magnetic resonance imaging|MRI]].<br>[[Magnetic resonance imaging|MRI]] has<br> better<br>sensitivity<br>in<br>detecting<br>[[ascites]]<br>fluid <br>and<br>[[mucocele]].
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* The echoes<br>within<br>pseudo-<br>myxoma <br>peritonei <br>are not <br>mobile.
* The echoes<br>within<br>[[Pseudomyxoma peritonei|pseudo-<br>myxoma <br>peritonei]] <br>are not <br>mobile.
* Echogenic<br>septations <br>within<br> the<br> gelatinous<br> ascites.
* Echogenic<br>septations <br>within<br> the<br> gelatinous<br> ascites.
* Scalloping <br>of the<br> [[hepatic]] <br>and<br>splenic <br>margins
* Scalloping <br>of the<br> [[hepatic]] <br>and<br>splenic <br>margins
| style="background: #F5F5F5; padding: 5px;" |18F-FDG<br> [[PET scan]]  
| style="background: #F5F5F5; padding: 5px;" |18F-FDG<br> [[PET scan]]  
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Depending on [[WHO]]<nowiki/>classification, whether it's low or high grade with cellular atypia or acellular mucin. ( DPAM, PMCA)
* Depending<br> on<br> [[WHO]]<nowiki/> <br>classification,<br> whether it is <br>low or high <br>grade<br> with <br>cellular atypia <br>or acellular mucin. <br>( DPAM, PMCA)
* Gelatinous [[ascites]] in peritoneum and [[visceral]]<nowiki/>organs,usually underneath the right hemidiaphragm, liver.
* Gelatinous<br> [[ascites]] <br>in peritoneum <br>and<br> [[visceral]]<br><nowiki/>organs,<br>usually <br>underneath<br> the right<br> hemidiaphragm,<br> liver.
* Omental cake
* Omental cake
** Immunohistochemisty
[[Immunohistochemistry|'''IHC''']]''':'''
*:* CK 20
*CK 20
*:* [[CDX2]]
* [[CDX2]]
*:* [[MUC2]]
* [[MUC2]]
*:* MUC5AC
* MUC5AC
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Carcinoid syndrome]]
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Carcinoid syndrome]]
Line 514: Line 513:
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<math>\uparrow</math>
| style="background: #F5F5F5; padding: 5px;" |<math>\uparrow</math>
| style="background: #F5F5F5; padding: 5px;" |Flushing
| style="background: #F5F5F5; padding: 5px;" |
 
* [[Flushing]]
Palpitation
* [[Palpitation]]
 
* [[Dyspnea]]
Dyspnea
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* TR               murmur
** [[Tricuspid regurgitation|TR]][[Heart murmur|murmur]]
* Wheezing
** [[Wheeze|Wheezing]]


| style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+</nowiki>
| style="background: #F5F5F5; padding: 5px;" |Depends  
| style="background: #F5F5F5; padding: 5px;" |Depends<br>on the<br>tumor<br>[[Neuroendocrine tumors laboratory findings|type]]:
on the
 
tumor [[Neuroendocrine tumors laboratory findings|type]]:
* Ki67
* Ki67
* N-terminal       pro–B-type natriuretic   peptide
* N-terminal<br>pro–B-<br>type<br>natriuretic<br>peptide
* [[Substance P]]
* [[Substance P]]
* [[Neurotensin]]
* [[Neurotensin]]
* [[Bradykinin]]
* [[Bradykinin]]
* [[Human chorionic gonadotropin]]
* Human<br>chorionic<br>gonadotropin
* Neuropeptide L
* Neuro-<br>peptide L
* [[Pancreatic polypeptide]]
* Pancreatic<br>polypeptide
*  
*  
| colspan="3" style="background: #F5F5F5; padding: 5px;" |Depends on the <br>primary tumor location and type
| colspan="3" style="background: #F5F5F5; padding: 5px;" |Depends on the <br>primary tumor location and type
Line 552: Line 547:


| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Salt and pepper nuclei  
* Salt<br> and<br> pepper<br> nuclei  
* Cellular uniformity
* Cellular<br> uniformity
* Central ovoid nucleus
* Central <br>ovoid<br> nucleus
* Presence of ribbons, trabeculae, nesting, glands, gyriform, pseudorosettes
* Presence of <br>ribbons,<br> trabeculae, <br>nesting, <br>glands,<br> gyriform,<br> pseudorosettes
* Insulinoma (Amyloid deposition)
* Insulinoma <br>(Amyloid <br>deposition)
* Somatostatinom (Psammoma bodies)
* Somatostatinom <br>(Psammoma <br>bodies)
* Hyaline globules
* Hyaline <br>globules
* '''IHC'''
[[Immunohistochemistry|'''IHC''']]''':'''
** Synaptophysin (almost always, strongly and diffusely expressed )
* Synaptophysin <br>(almost<br> always, <br>strongly <br>and <br>diffusely<br> expressed )
** Chromogranin A
* CGA
** CD56 and PGP ( less specific)
* CD56 and PGP<br>( less <br>specific)
** PDX1 and ISL1
* PDX1
* ISL1
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Appendicitis differential diagnosis|Appendicitis]] <sup>3</sup>
| colspan="2" style="background: #DCDCDC; padding: 5px;" |[[Appendicitis differential diagnosis|Appendicitis]] <sup>3</sup>
Line 571: Line 567:
   
   
| style="background: #F5F5F5; padding: 5px;" |[[Nausea and vomiting|Nausea<br> &<br>vomiting]],<br>decreased
| style="background: #F5F5F5; padding: 5px;" |[[Nausea and vomiting|Nausea<br> &<br>vomiting]],<br>decreased
appetite
[[appetite]]


| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
| style="background: #F5F5F5; padding: 5px;" |<nowiki>+/-</nowiki>
Line 578: Line 574:
* Rebound<br>tenderness
* Rebound<br>tenderness
* Abdominal<br>guarding
* Abdominal<br>guarding
* Rovsing's<br>sign
* [[Rovsing's sign|Rovsing's<br>sign]]
* Psoas<br>sign
* [[Psoas sign|Psoas<br>sign]]
* Obturator<br>sign
* [[Obturator sign|Obturator<br>sign]]
* TR exam<br>might reveal<br>tenderness<br>in the<br>rectovesical<br>pouch  
* [[Rectal examination|TR exam]]<br>might reveal<br>tenderness<br>in the<br>[[Rectovesical excavation|rectovesical<br>pouch]]
* [[Tachypnea]]  
* [[Tachypnea]]  
* Tachycardia  
* Tachycardia  
Line 590: Line 586:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Leukocytosis]]
* [[Leukocytosis]]
* Left shift
* [[Left shift]]
| style="background: #F5F5F5; padding: 5px;" |  
| style="background: #F5F5F5; padding: 5px;" |  
*Appendiceal<br> wall<br> thickening<br> /perforation
*Appendiceal<br> wall<br> thickening<br> /perforation


*Peri-<br>appendiceal<br>inflammation,<br>fluid<br>accumulation,<br>
*Peri-<br>appendiceal<br>[[inflammation]],<br>fluid<br>accumulation,<br>
*Fat<br>stranding
*Fat<br>stranding


Line 601: Line 597:
* Dilated<br> appendix
* Dilated<br> appendix
* Peri-<br>appendiceal <br> fluid<br>  collection
* Peri-<br>appendiceal <br> fluid<br>  collection
* Distinct <br> appendix<br>  wall<br>  layers
* Distinct <br> [[Vermiform appendix|appendix]]<br>  wall<br>  layers
| style="background: #F5F5F5; padding: 5px;" |[[Tc-99m]] <br> labeled <br> anti-<br> [[CD15]]<br>  [[antibodies]]  
| style="background: #F5F5F5; padding: 5px;" |[[Tc-99m]] <br> labeled <br> anti-<br> [[CD15]]<br>  [[antibodies]]  
| style="background: #F5F5F5; padding: 5px;" |Evidences <br> of<br>  [[inflammation]]
| style="background: #F5F5F5; padding: 5px;" |Evidences <br> of<br>  [[inflammation]]
Line 640: Line 636:


modalities
modalities
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histo-
pathology
|}
|}


<small><sup>1</sup></small> Adenocarcinomas usually present with appendicitis, barely they might present with [[Pseudomyxoma peritonei]]; meanwhile Pseudomyxoma peritonei is more prevalent in perforated mucocele, goblet cell tumor or high stages of adenocarcinoma.
<small><sup>1</sup></small> [[Adenocarcinoma]]<nowiki/>s usually present with appendicitis, barely they might present with [[Pseudomyxoma peritonei]]; meanwhile [[pseudomyxoma peritonei]] is more prevalent in perforated [[mucocele]], goblet cell tumor or high stages of [[Adenocarcinoma|adenocarcinoma.]]


<sup>2</sup> Generally appendix carcinoids are asymptomatic, they were only become symptomatic if they metastasize to the liver, or in rare cases make an obstruction and present with appendicitis which is quit uncommon in appendiceal carcinoids compared to appendiceal adenocarcinoma.  Any patient with carcinoid syndrome should be evaluated for appendix carcinoids.
<sup>2</sup> Generally [[Vermiform appendix|appendix]] [[Carcinoid Tumor|carcinoids]] are [[asymptomatic]], they were only become symptomatic if they [[Liver mass|metastasize to the liver,]] or in rare cases make an obstruction and present with appendicitis which is quit uncommon in appendiceal carcinoids compared to appendicea[[Adenocarcinoma|l adenocarcinoma]].  Any patient with [[carcinoid syndrome]] should be evaluated for [[Carcinoid|appendix carcinoid]]<nowiki/>s.


<sup>3</sup> Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer.
<sup>3</sup> Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer.


<sup>4</sup> '''Imaging''' '''is not a reliable method to''' '''distinguish between neoplastic and''' '''nonneoplastic lesions''', hence every patient should undergo surgery, appendectomy and histopathologic evaluation of the lesion
<sup>4</sup> '''[[Imaging]]''' '''is not a reliable method to''' '''distinguish between [[Cancer|neoplastic]] and''' '''[[Neoplasm|non-neoplastic]] lesions''', hence every patient should undergo [[surgery]], appendectomy and [[Histopathology|histopathologic]] evaluation of the lesion


<nowiki>*</nowiki>'''Abbreviations:''' RLQ: Right Lower Quadrant, AFP: Alpha Fetoprotein, HCG: Human chorionic gonadotropin, LDH: Lactate Dehydrogenase, CEA: Carcinoembryonic antigen, CA 125: Cancer antigen 125, 5-HIAA: Urinary 5-hydroxyindoleacetic acid , CgA: Serum Chromogranin A ,PU: Periumbelical, TR: Tricuspid regurgitation  
<nowiki>*</nowiki>'''Abbreviations:''' RLQ: Right Lower Quadrant, [[Alpha-fetoprotein|AFP]]: [[Alpha-fetoprotein]], [[Human chorionic gonadotropin|HCG: Human chorionic gonadotropin]], [[Lactate dehydrogenase|LDH: Lactate Dehydrogenase]], [[Carcinoembryonic antigen|CEA: Carcinoembryonic antigen]], [[CA-125|CA-125: Cancer antigen 125]], [[5-Hydroxyindoleacetic acid|5-HIAA: Urinary 5-hydroxyindoleacetic acid]] , [[Chromogranin A|CgA: Serum Chromogranin A]] ,PU: Periumbelical, TR: [[Tricuspid regurgitation]]


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Surgery]]
[[Category:Medicine]]
[[Category:Emergency medicine]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Differential diagnosis]]

Latest revision as of 13:26, 15 July 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Appendix cancer must be differentiated from benign appendix lesions (mucocele, acute appendicitis), colorectal cancers, adenexal masses (ovarian tumors), and carcinoid tumors of the other organs.

Differentiating appendix cancer from other Diseases

Diseases Clinical manifestations Para-clinical findings
Symptoms Physical examination
Lab Findings Imaging Histo-

pathology

Abdo-
minal
pain
Change in girdle size Bowel

freq-

uency

Other

symptoms

Abdo-
minal
mass
Abdo-
minal
tender-
ness
Other

physical

exami-

nation

findings

5-HIAA
and/or
CgA
Other lab findings CT scan MRI Utra-

sounography

Other

diagnostic

studies

and

imaging

modalities

Appendix cancer Adeno-

carcinoma1

+/- -/+ <math>\downarrow</math> - - -
  • Soft
    tissue
    thickening
  • Wall
    irregularity
  • Presence
    of
    pseudo-
    myxoma
    peritonei
  • Calcification
  • Internal
    septations
  • Peri
    appendiceal
    fat
    stranding
    and
    intra-
    peritoneal
    free fluid
    which is a
    nonspecific
    finding
  • Cystic
    lesion
  • Diffusion
    weighted
    MRI
    has
    been
    shown to
    be
    the
    modality
    of choice
    for
    peritoneal
    carcino-
    matosis
  • Increased
    fluid
    signal on
    T2 weighted sequence
  • Soft
    tissue
    mass in
    the
    appendix
  • Invasion to
    the other
    structures
  • Dilated
    appendix
  • Peri-
    appendiceal
    fluid
    collection
  • Distinct
    appendix
    wall
    layers
Positron
emission
tomography

(PET)
Gross
pathology
:
  • Gray/yellow
    color
  • Cystic
    structures
    with
    angiolymphatic
    invasion
  • Appendix
    might be
    buried
    within
    the mass

Microscopic
pathology:

IHC:

  • MUC 2
  • MUC5AC
  • CK 8/18
  • CK 13
  • CK 19
  • CK 20
Carcinoid

tumor2

+/- - <math>\uparrow</math> - - +

Ki67:
a reliable
marker of
cell
proliferation

Gross
pathology
:
  • Prevalent
    at the
    tip of
    appendix
  • Generally
    less than
    1 cm
  • Gray or
    yellow
  • Well-
    demarcated
    firm
  • Intramural
    nodules
    that may
    narrow or
    obliterate
    appendiceal
    lumen
  • Proximal
    tumors
    may cause
    obstruction
    and
    appendicitis

Microscopic
pathology:

  • Insular
    growth
    pattern
    of solid
    islands of
    uniform
    polygonal
    cells with
    minimal
    pleomorphism
  • Retraction
    of
    peripheral
    tumor
    cells from
    stroma
  • Angio-
    lymphatic
    invasion
    is common
  • Granular
    eosinophilic
    cytoplasm
    with either
    diffusely
    scattered
    or
    peripherally
    clumped
    granules
  • Two types
    of well
    differentiated
    tumors:
    EC cell
    (serotonin
    producing)
    and rarely
    L-cell
    (enteroglucagon
    or
    peptide YY
    producing)

IHC:

  • Might be
    positive for
    S100
Goblet

cell

carcinoid

+ +/- <math>\uparrow</math> +/- +
  • Ascites
  • Shifting
    dullness
  • May
    appear
    anemic
+/- Unfortunately,
compared to the other carcinoid tumors of appendix,
GCC is more aggressive and
patients with GCC generally present at higher stages.
Hence, in addition to
the above mentioned
general findings for appendix cancers,
imaging studies should
look for evidences of peritoneal involvement,
bone metastasis, lymphadenopathy,
and metastatic lesions
in ovaries and/or prostate.

Gross
pathology
:

  • No gross
    tumor might
    be present
  • Thickened
    appendiceal
    wall

Microscopic
appearance:

  • GCC Generally
    spares mucosa
    and
    infiltrates
    muscularis
    propria
    and
    peri-
    appendiceal
    fat
  • Tumor
    cell clusters
  • Crypt-like
    structures
  • Tubules of
    mucus-secreting
    cells distended
    with mucin
    resembling
    goblet cells
  • Eosinophilic
    cytoplasm
    resembling
    carcinoid
    tumors
  • Pools of
    extracellular
    mucin
  • Scattered
    Paneth cells
    in tumors
    with crypt
    like
    structures
  • Extensive
    perineural
    invasion
  • Carcinomatous
    growth
    pattern:
  • Cribriform
    growth
    pattern,
    solid
    sheets of
    infiltrating
    signet ring
    cells
  • Nuclear
    pleomorphism
  • Increased
    mitotic
    activity
Diseases Abdo-
minal
pain
Change in girdle size Bowel

freq-

uency

Other

symptoms

Abdo-
minal
mass
Abdo-
minal
tender-
ness
Other

physical

exami-

nation

findings

5-HIAA
and/or
CgA
Other lab findings CT scan MRI Utra-

sounography

Other

diagnostic

studies

and

imaging

modalities

Histo-

pathology

Appendix Mucocele Mucosal

hyperplasia

- - -
  • Generally asympto-
    matic
  • Benign
    even
    after
    rupture
- +/- N/A - N/A
  • low
    attenuation
    well
    defined
    mass in
    RLQ
    near
    cecum
  • Inflammation
    is the key to
    distinguish
    between
    appendicitis
    and
    mucocele
  • Wall
    thickness
    does not
    distinguish
    between
    malignant
    and
    benign
    mucocele
  • Intramural
    nodule
    is a sign of
    neoplastic
    lesions. 4
Rounded
right iliac
fossa mass
  • T1: The
    signal
    depends
    on
    the mucin
    concen-
    tration,
    may be
    from
    hypointense
    to
    isointense
  • T2:
    Hyperintense
  • Histo-
    logically
    benign
  • Dilated
    fluid
    filled
    appendix
    in the
    RLQ.
  • Thin
    appendiceal
    wall
  • A focus
    of
    hyper-
    echogenicity
  • Since
    generally
    there is
    no inflammation
  • Surrounding
    fat
    is normal.
  • No peri-
    appendiceal
    fluid or
    collection
N/A Similar
to
hyperplastic
colon
polyp
Simple

or

retention

cyst

- - - - +/- - - N/A Degenerative
epithelial
changes
because of
obstruction
Mucinous cyst-

adenomas

+/- +/- <math>\uparrow</math><math>\downarrow</math>
  • Generally asympto-
    matic
  • Rupture
    may
    lead
    to
    Pseudo-
    myxoma
    peritonei
+/- +/- If develop

pseudo-
myxoma
peritonei
:

-
  • Histo-
    logically
    benign
  • Similar
    to
    colon
    adenomatous
    polyps or
    villous
    adnomas
Mucinous cystadeno-

carcinomas

+/- +/- <math>\uparrow</math><math>\downarrow</math> +/- +/- - -
  • Glandular
    invasion
    into the
    stoma
  • Pseudo-
    myxoma
    peritonei
Diseases Abdo-
minal
pain
Change in girdle size Bowel
freq-
uency
Other

symptoms

Abdo-
minal
mass
Abdo-
minal
tender-
ness
Other

physical
exami-
nation
findings

5-HIAA
and/or
CgA
Other lab findings CT scan MRI Utra-
sounography
Other
diagnostic
studies
and
imaging
modalities
Histo-

pathology

Ovarian cancer +/- +/- +/-<math>\downarrow</math> + +/- -
  • Adnexal
    mass
  • Adenexal
    Cyst
    (simple
    or
    complex)
  • Fluid
    accumulation
  • Endometrial
    thickening
  • Calcification
  • Pleural
    effusion
  • Peritoneal
    involvement
  • Lympha-denopathy
  • Adnexal
    mass
  • Adenexal
    cyst
    (simple
    or
    complex)
  • Except for
    Thecoma,
    ovarian
    masses
    are
    generally hyperintense
    on T1 and
    hypo or
    sointense
    on
    T2 imaging
  • Fluid
    accumulation
  • Endometrial
    thickening
  • Calcification
  • Pleural
    effusion
  • Peritoneal
    involvement
  • Lympha-
    denopathy
  • Adnexal
    mass
  • Adenexal
    cyst
    (simple
    or
    complex)
  • Fluid
    accumulation
  • Increased
    Doppler
    flow
  • Endometrial
    thickening
  • Calcification
N/A Depends
on the
tumor type.
You may
find the
details
here.
Colorectal cancer +/- +/- <math>\uparrow</math><math>\downarrow</math> + +/- Colonoscopy

Adeno-

carcinoma

Carcinoids

-/+(Carcinoid tumors)
  • Tumor
    mass
    and
    the
    extension
    of
    tumor to
    other
    structures
Generally
not
recommended:
may
evaluate
liver metastasis
or presence
of fluid
in abdominal
cavity, but it is
neither
sensitive
nor
specific.
PET
scan
,
Endoscopy,
Colonoscopy,

Barium enema

  • Depends
    on the
    tumor
    type.
    You will
    find more
    information
    here
Pseudomyxoma

peritonei

+ + <math>\uparrow</math><math>\downarrow</math> Bloating - + Ascites

Shifting dullness

-
  • Nonspecific
  • Depends
    on the
    etiology
    of the
    disease
  • Low-
    attenuation
    Scalloping
    of the
    visceral
    surfaces
    differentiates
    pseudo-
    myxoma

    from other
    causes of
    peritonitis.
  • Typically
    does not
    invade
    visceral
    organs
    or spread
    by lymphatic
    or
    hemato-
    genous
    routes
    unlike
    mucinous
    carcino-
    matosis

Charact-
erized
by a mass
which is
hypointense
on
T1-weighted
MRI
and
hyperintense
on
T2-weighted
MRI.
MRI has
better
sensitivity
in
detecting
ascites
fluid
and
mucocele.

  • The echoes
    within
    pseudo-
    myxoma
    peritonei

    are not
    mobile.
  • Echogenic
    septations
    within
    the
    gelatinous
    ascites.
  • Scalloping
    of the
    hepatic
    and
    splenic
    margins
18F-FDG
PET scan
  • Depending
    on
    WHO
    classification,
    whether it is
    low or high
    grade
    with
    cellular atypia
    or acellular mucin.
    ( DPAM, PMCA)
  • Gelatinous
    ascites
    in peritoneum
    and
    visceral
    organs,
    usually
    underneath
    the right
    hemidiaphragm,
    liver.
  • Omental cake

IHC:

Carcinoid syndrome -/+ - <math>\uparrow</math> - - + Depends
on the
tumor
type:
Depends on the
primary tumor location and type
  • Salt
    and
    pepper
    nuclei
  • Cellular
    uniformity
  • Central
    ovoid
    nucleus
  • Presence of
    ribbons,
    trabeculae,
    nesting,
    glands,
    gyriform,
    pseudorosettes
  • Insulinoma
    (Amyloid
    deposition)
  • Somatostatinom
    (Psammoma
    bodies)
  • Hyaline
    globules

IHC:

  • Synaptophysin
    (almost
    always,
    strongly
    and
    diffusely
    expressed )
  • CGA
  • CD56 and PGP
    ( less
    specific)
  • PDX1
  • ISL1
Appendicitis 3 PU,
RLQ
- <math>\uparrow</math><math>\downarrow</math> Nausea
&
vomiting
,
decreased

appetite

+/- + -
  • Appendiceal
    wall
    thickening
    /perforation
  • Peri-
    appendiceal
    inflammation,
    fluid
    accumulation,
  • Fat
    stranding
Increased
fluid
signal
on T2
weighted
sequence
Evidences
of
inflammation
  • Dilated
    appendix
  • Peri-
    appendiceal
    fluid
    collection
  • Distinct
    appendix
    wall
    layers
Tc-99m
labeled
anti-
CD15
antibodies
Evidences
of
inflammation
Diseases Abdo-
minal
pain
Change in girdle size Bowel

frequ- f ency

Other

symptoms

Abdo-
minal
mass
Abdo-
minal
tender-
ness
Other

physical

exami-

nation

findings

5-HIAA
and/or
CgA
Other lab findings CT scan MRI Utra-

sounography

Other

diagnostic

studies

and

imaging

modalities

Histo-

pathology

1 Adenocarcinomas usually present with appendicitis, barely they might present with Pseudomyxoma peritonei; meanwhile pseudomyxoma peritonei is more prevalent in perforated mucocele, goblet cell tumor or high stages of adenocarcinoma.

2 Generally appendix carcinoids are asymptomatic, they were only become symptomatic if they metastasize to the liver, or in rare cases make an obstruction and present with appendicitis which is quit uncommon in appendiceal carcinoids compared to appendiceal adenocarcinoma. Any patient with carcinoid syndrome should be evaluated for appendix carcinoids.

3 Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer.

4 Imaging is not a reliable method to distinguish between neoplastic and non-neoplastic lesions, hence every patient should undergo surgery, appendectomy and histopathologic evaluation of the lesion

*Abbreviations: RLQ: Right Lower Quadrant, AFP: Alpha-fetoprotein, HCG: Human chorionic gonadotropin, LDH: Lactate Dehydrogenase, CEA: Carcinoembryonic antigen, CA-125: Cancer antigen 125, 5-HIAA: Urinary 5-hydroxyindoleacetic acid , CgA: Serum Chromogranin A ,PU: Periumbelical, TR: Tricuspid regurgitation

References